Teng Xiao-Dong, Wang Li-Jun, Yao Hong-Tian, Li Jun, Ding Wei, Yan Li-Ping
Department of Pathology, The 1st Affiliated Hospital, Zhejiang University, Hangzhou 310003, China.
Zhonghua Bing Li Xue Za Zhi. 2004 Jun;33(3):212-6.
To study immunohistochemical expression of cytokeratin19 (CK19), galectin-3 (Gal-3) and HBME-1 in thyroid lesions and to assess their usefulness as markers in the differential diagnoses of thyroid nodular lesions.
Immunohistochemical staining was performed on formalin-fixed paraffin-embedded tissue of 21 cases of nodular goiters, 14 cases of toxic goiters, 15 cases of follicular adenomas (FA), 13 cases of follicular carcinomas (FC), 13 cases of follicular variant papillary carcinomas (FVPC) and 48 cases of classic papillary carcinomas (CPC).
All three markers were expressed in the cytoplasm with no or weak expression in benign lesions and diffuse and strong in malignant cases. Positive expressions of CK19, Gal-3 and HBME-1 were present in 11of 21, two of 21, four of 21 in nodular goiters, seven of 14, one of 14, one of 14 in toxic goiters, nine of 15, two of 15, two of 15 in FA, 10 of 13, eight of 13, seven of 13 in FC, 13 of 13, 11 of 13, 12 of 13 in FVPC, and 48 of 48, 45 of 48, 46 of 48 in CPC. The expression rates of the three markers between benign lesions (nodular goiters, toxic goiters and FA) and malignant lesions (FA, FVPC and CPC) were statistically significant. Among the three follicular lesions (FA, FC and FVPC), the differences were statistically significant as well. Nine, seven and six cases were negative for all three markers in nodular goiters, toxic goiters and FA, respectively. Only one case in FC was negative for all three markers, no case was all negative in FVPC and CPC; the rate of one case with two or more positive marker expression in nodular goiters, toxic goiters, FA, FC, FVPC and PC was 14.2% (3/21), 21.43% (3/14), 20.0% (3/15), 69.2% (9/13), 92.3% (12/13), 100.0% (48/48), the differences between benign lesions and malignant lesions and between FA, FC and FVPC were also statistically significant.
Immunohistochemical stains of CK19, Gal-3 and HBME-1, especially when used in combination, can be an important adjunct to the histopathological diagnoses of thyroid lesions.
研究细胞角蛋白19（CK19）、半乳糖凝集素-3（Gal-3）和人鼠桥粒芯蛋白-1（HBME-1）在甲状腺病变中的免疫组化表达，并评估它们作为甲状腺结节性病变鉴别诊断标志物的效用。
对21例结节性甲状腺肿、14例毒性甲状腺肿、15例滤泡性腺瘤（FA）、13例滤泡癌（FC）、13例滤泡型乳头状癌（FVPC）和48例经典型乳头状癌（CPC）的福尔马林固定石蜡包埋组织进行免疫组化染色。
所有三种标志物均在细胞质中表达，在良性病变中无表达或弱表达，在恶性病例中呈弥漫性强表达。结节性甲状腺肿中CK19、Gal-3和HBME-1的阳性表达分别为21例中的11例、21例中的2例、21例中的4例；毒性甲状腺肿中分别为14例中的7例、14例中的1例、14例中的1例；FA中分别为15例中的9例、15例中的2例、15例中的2例；FC中分别为13例中的10例、13例中的8例、13例中的7例；FVPC中分别为13例中的13例、13例中的11例、13例中的12例；CPC中分别为48例中的48例、48例中的45例、48例中的46例。良性病变（结节性甲状腺肿、毒性甲状腺肿和FA）与恶性病变（FC、FVPC和CPC）之间三种标志物的表达率差异有统计学意义。在三种滤泡性病变（FA、FC和FVPC）之间差异也有统计学意义。结节性甲状腺肿、毒性甲状腺肿和FA中分别有9例、7例和6例三种标志物均为阴性。FC中仅1例三种标志物均为阴性，FVPC和CPC中无病例三种标志物均为阴性；结节性甲状腺肿、毒性甲状腺肿、FA、FC、FVPC和PC中一种或多种标志物阳性表达的病例率分别为14.2%（3/21）、21.43%（3/14）、20.0%（3/15）、69.2%（9/13）、92.3%（12/13）、100.0%（48/48），良性病变与恶性病变之间以及FA、FC和FVPC之间的差异也有统计学意义。
CK19、Gal-3和HBME-1的免疫组化染色，尤其是联合使用时，可作为甲状腺病变组织病理学诊断的重要辅助手段。
Zotero 插件